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ABSTRACT 
Insulin-like growth factor-II (IGF-II) is an important regulator of 
embryonic growth and differentiation, but its function in postnatal life 
is unclear. To address this point, we generated transgenic mice harbor- 
ing fusion genes in which a human IGF-II complementary DNA is 
placed under the transcriptional control of the rat phosphoenolpyruvate 
carboxykinase promoter. Transgene-specific messenger RNA was de- 
tected in liver, kidney, and several parts of the gut. Serum IGF-II levels 
in transgenic mice were 2-3 times higher than those in controls and 
increased after starvation. Circulating IGF-I correlated negatively and 
IGF-binding protein-2 (IGFBP-2) positively with IGF-II levels, sug- 
gesting that IGF-I is displaced from IGFBPs by IGF-II and that IGF- 
II is a major regulator of IGFBP-2. Serum levels of IGFBP-3 and 
IGFBP-4 tended to be higher in phosphoenolpyruvate carboxykinase- 
IGF-II transgenic mice than in controls, as evaluated by ligand blot 
analysis. Starvation reduced serum IGF-I, but increased IGFBP-2 in 
transgenic mice more markedly than in controls. Fasting insulin levels 
were significantly reduced in transgenic mice, whereas glucose levels 
were not influenced by elevated IGF-II. The body growth of 4- and 12- 
week-old mice was not significantly influenced by elevated IGF-II, but 
transgenic mice displayed increased kidney and testis weight at the age 
of 4 weeks, and increased adrenal weight at the age of 12 weeks. Our 
results demonstrate that elevated IGF-II in postnatal life has multiple 
endocrine consequences and subtle time-specific effects on organ 
growth. (Endocrinology 135: 1877-1886,1994) 
A LTHOUGH the biological roles of insulin-like growth factor-I (IGF-I) as both a hormone and a paracrine 
growth factor are becoming increasingly clearer (for review, 
see Refs. 1 and 2), no overall concept has emerged of the 
physiological function of IGF-II in growth and metabolism. 
The role of IGF-II has widely been postulated to be a fetal 
growth-promoting hormone. The most direct evidence for 
this was provided by DeChiara et al. (3), who inactivated the 
IGF-II gene in mice by gene targeting. The growth of fetuses 
lacking functional IGF-II expression was impaired, but post- 
natal growth paralleled that of control littermates, suggesting 
that IGF-II does not play a major role in postnatal growth. 
These studies also demonstrated that the mouse IGF-II gene 
is subject to genomic imprinting and that only the paternal 
allele is active (4). Furthermore, IGF-II is known to stimulate 
the growth and metabolism of preimplantation mouse em- 
bryos in vitro (5). 
IGF-II messenger RNA (mRNA) expression is high in most 
fetal tissues and declines after birth, except in neural tissue 
(6-8). Postnatal plasma levels of IGF-II are essentially low 
in rats and mice, but in other species, such as sheep and 
guinea pig, serum IGF-II levels decline somewhat after birth, 
but stay relatively high (2). In man, postnatal levels are even 
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higher than prenatal levels; they increase with gestational 
age and rise during the first weeks of life, with no pubertal 
increase (9, 10). Postnatal IGF-II expression in man is driven 
by an alternative promoter, which starts after birth and 
confers IGF-II gene expression mainly in the liver (11, 12). 
Elevated IGF-II expression is found in a variety of malig- 
nancies in humans (for review, see Ref. 13), in liver tumors 
of transgenic mice harboring the early region of simian virus- 
40 under the control of either human antithrombin-III reg- 
ulatory sequences (14,15) or the major urinary protein (MUP) 
promoter (15), and in hepatic neoplasms in transgenic mice 
containing the pre-S/S region of hepatitis-B virus controlled 
by the mouse albumin promoter and enhancer (15). 
The failure to demonstrate clear roles for IGF-II in post- 
natal growth physiology and pathology invited the genera- 
tion of an animal model with postnatally elevated IGF-II 
mRNA and protein. We, therefore, produced transgenic mice 
carrying fusion genes in which a human IGF-II complemen- 
tary DNA (cDNA) is placed under the transcriptional control 
of the rat phosphoenolpyruvate carboxykinase (PEPCK) pro- 
moter. In this first study, we investigated the dietary regu- 
lation of PEPCK-IGF-II transgene expression and effects on 
IGF-I, IGF-binding proteins (IGFBPs), insulin, and glucose 
levels. Furthermore, we characterized the effects of elevated 
IGF-II on body and organ growth at 4 and 12 weeks of age. 
Materials and Methods 
Construction of the PEPCK-IGF-II gene construct 
A 550.basepair (bp) fragment of the PEPCK promoter was amplified 
from the plasmid pTZ18R-PEPCK-P-globin (a gift from Dr. St. Rose- 
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John, Institut fti Biochemie, RTWH Aachen, Germany) by polymerase 
chain reaction. PEPCK promoter-specific sense and antisense oligonu- 
cleotides 5’-CGTACGACTAGTGAATTCCCTTCTCATGACCTTT-3’ 
and 5’-CTTTAGGCCGCTCTGCGAGACTCGAGCGAGCGCTAG-3’ were de- 
signed according to the available DNA sequence in the GENBANK 
database (accession no. KOr299), including a flanking SpeI site (italicized) 
in the sense oligo and a Sac1 site (italicized) in the antisense oligo. The 
polymerase chain reaction product was blunted by T4 DNA polymerase 
and inserted into the SmaI site of pBluescript II KS (Stratagene, La 
Jolla, CA). The DNA sequence was verified by automatic sequencing 
with the Bio-Rad sequencing system (Richmond, CA). The PEPCK pro- 
moter was inserted up-stream of the rat insulin-II intron A as a SpeI- 
Sac1 fragment in a mammalian expression vector based on pCMV5, 
resulting in pPEPCK-int. Finally, a 768-bp BamHI-PstI fragment span- 
ning the coding region of the human IGF-II gene (16) and 80 bp of the 
5’-untranslated region (17) was isolated from vector pIJC12IGF-II 
(obtained from Dr. R. Koshy, Department of Virology, Royal Postgrad- 
uate Medical School, London, United Kingdom) and cloned into 
pPEl’CK-int down-stream of the rat insulin II intron. From the resulting 
plasmid PEPCK-int-IGF-II, a 2-kilobase (kb) SpeI-BstXI fragment was 
excised, gel purified, and used for microinjection. The fragment includes 
550 bp of the I’EI’CK promoter, 120 bp of rat insulin II intron A 
sequences, the IGF-II-coding region, and 420 bp of the terminating 
sequences of the human GH gene (Fig. 1). 
Production of transgenic mice and animal husbandry 
A solution containing 2 pg/ml of the DNA fragment described above 
in 10 mmol/liter Tris-HCl (pH 7.4) and 0.25 mmol/liter EDTA buffer 
was used for microinjection into pronuclei of zygotes from superovulated 
B6D2Fl mice. Injected zygotes were transferred to synchronized recipi- 
ents (NMRI). Mice were purchased from Charles River-WIGA (Sulzfeld, 
Germany). 
The presence of the PEPCK-IGF-II gene construct in 3-week-old 
animals was shown by Southern blot analysis. DNA was extracted from 
tail tips according to previously described methods (18). Aliquots (10 rg) 
were digested with PstI, fractionated on 1% agarose gels in 1 X TBE (89 
mmol/liter Tris-borate and 1 mmol/liter EDTA), and blotted under alkali 
conditions to Hybond N+ membranes (Amersham, Arlington 
Heights, IL). Filters were prehybridized for 3 h at 65 C in 1 mol/liter 
NaCl, 1% sodium dodecyl sulfate (SDS), 1 mmol/liter EDTA, and 10 
mmol/liter Tris-HCl containing 10% dextran sulfate. Hybridization was 
performed overnight in the same buffer containing a ?-labeled (lo7 
cpm/ml) 782-bp IGF-II cDNA probe excised from pUC12-IGF-II with 
PstI. The membranes were washed for 10 min at room temperature in 2 
X SSC (0.3 mol/liter NaCl, 0.03 mol/liter Na3 citrate.2H20) and twice 
for 30 min at 65 C in 0.1 X SSC containing 1% SDS and then exposed 
to x-ray film (X-Omat, Eastman Kodak, Rochester, NY). 
Transgenic founder animals were mated to nontransgenic mice to set 
up transgenic lines. All animals were kept under conventional (nonbar- 
rier) conditions and had free access to pelleted diet (Altromin 1324; 
Altrornin, Lage, Germany) and tap water. A detailed description of 
housing conditions, including the pathogens present in the colony, was 
provided previously (19). 
RNA analysis 
Tissue samples (-100 mg) were obtained from PEPCK-IGF-II trans- 
genie mice and nontransgenic littermates and immediately frozen in 
Spel ECORI PStl BstXl 
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FIG. 1. Schematic representation of PEPCK-IGF-II. The construct 
was cloned as described in Materials and Methods and includes the 
550-bp PEPCK promoter, 120-bp rat insulin II intron A sequences, the 
768-bp human IGF-II cDNA, and 420 bp of the terminating sequences 
of the human GH gene. Restriction sites as well as translation initiation 
(ATG) and transcription termination (AATAAA and GGTGTCCT) 
are indicated. 
liquid nitrogen. For analysis, the tissues were homogenized in 2 ml 4 
mol/liter guanidine thiocvanate usine. an Ultra-Turrax Svstem T25 llanke 
& Kunkec Staufen, Germany). RNA was further purified by isopycnic 
gradient centrifugation in cesium trifluoroacetate (20), quantified by UV 
spectrometry, glyoxylated, and fractionated on a 1.1% agarose gel. 
Electrophoresed RNA was transferred to Hybond N filters (Amersham), 
which were hybridized with an IGF-II-specific 3ZP-labeled complemen- 
tary RNA probe produced by Amersham multiprime labeling system. 
The complementary RNA probe was obtained by in vitro transcription 
of the PstI IGF-II fragment from pUC12-IGF-II, which had been cloned 
into pBluescript II KS (Stratagene). Hybridization was carried out under 
stringent conditions in 50 mmol/liter sodium phosphate buffer contain 
ing 50% formamide, 6 X SSC, 10 mmol/liter EDTA, 2 X Denhardt’s 
solution (0.4 g/liter Ficoll 400, 0.4 g/liter polyvinylpyrrolidone, and 0.4 
g/liter BSA), 1% SDS, and 250 pg/ml denaturated salmon sperm DNA 
at 50 C for 12 h. Filters were washed in 0.2 X SSC-0.5% SDS at 65 C 
for 30 min before autoradiography. The size of the mRNA transcripts 
was determined by comparison of relative mobilities with a RNA size 
standard (Gibco-BRL, Gaithersburg, MD). As a loading control and to 
check the integrity of the RNA samples, filters were stained by methyl- 
ene blue (21) after autoradiography. 
Serum sampling, hormone and IGFBP assays, and glucose 
determination 
Blood samples were taken by orbital puncture from mice under ether 
anesthesia; these were stored at 4 C for 30 min and centrifuged twice 
for 10 min each time at 15,000 X g to obtain serum. Fasting serum 
samples were taken after a 14-h food deprivation period. Serum samples 
were stored in loo-p1 aliquots at -20 C until further analysis. 
Serum concentrations of IGF-II, IGF-I, and IGFBP-2 were determined 
by RIA, as described previously (10, 22, 23). For IGF-II measurements, 
serum samples were extracted by acid-ethanol. Residual BPS in the 
extract were blocked with an excess of recombinant human IGF-I (25 
rig/tube). For IGF-I determination, acid-ethanol extraction was not nec- 
essary due to the high affinity of the first antibody. Serum samples were 
diluted 1:150 with a 10 rn~ phosphate buffer (pH 2.8) to dissociate IGFs 
from IGFBPs. Upon reneutralization with assay buffer, an excess of 
recombinant human IGF-II (Mediagnost, Tiibingen, Germany) was 
added simultaneously to block IGFBP-binding sites. For IGFBP-2 meas- 
urements, serum samples were diluted 1:30 in assay buffer. 
Ligand blot analysis of serum IGFBPs was performed according to 
the method of Hossenlopp et al. (24), using [‘251]IGF-II as tracer. Serum 
samples were diluted 1:3 with PBS before analysis. Quantitative evalu- 
ation of ligand blots was carried out according to the method of Zapf et 
al. (25) by cutting out marked bands from the nitrocellulose membrane 
and counting them in a y-counter. 
Serum insulin concentrations were measured using a commercially 
available RIA kit (INSULIN-CT, CIS Bio International, Gif-sur-Yvette, 
France) for human insulin with 89.5% cross-reactivity for rat insulin. 
Intraassay coefficients of variation were 9.3% and 2.2% (five replicates) 
for mouse serum samples containing 17.2 and 50.4 pIU insulin/ml, 
respectively. The interassay coefficient of variation was 9.7% (three 
replicates) for the sample containing 17.2 rIU insulin/ml. 
Fasting serum glucose levels were determined using the Glucoquant- 
Hexokinase method on a Reflotron analyzer (Boehringer Mannheim, 
Germany). 
Analysis of body and organ growth 
Body weight and body dimensions as well as organ weights of 
PEPCK-IGF-II transgenic mice and littermate controls were determined 
at 4 and 12 weeks of age. After taking the body weight, animals were 
killed by an overdose of ketamine and xylazine. External body dimen- 
sions (crown-rump length, nose-rump length, and total body length) 
were determined as described previously (26). Heart, lung, spleen, 
pancreas, kidneys, adrenal glands, liver, gastroenteric tract, thymus, 
salivary glands, brain, and testes were dissected, blotted dry on tissue 
paper, and weighed to the nearest milligram. Furthermore, the weight 
of mesentery and fat tissue surrounding the genital organs and kidneys 
was determined, as the amount of intraabdominal fat tissue is correlated 
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with the total body fat content (27). Finally, the weights of skin and 
empty carcass were determined to the nearest gram. 
Statistical analysis 
Analysis of variance was performed on data obtained from PEPCK- 
IGF-II transgenic mice and controls for hormone and glucose levels as 
well as body measurements and organ weights. A statistical model was 
designed to estimate the effects of group (transgenic or control), sex, 
age, and the interaction between group and sex. The general linear 
models procedure (28) was used to calculate least squares means (LSMs) 
and SES of LSMs. Statistically significant differences between LSMs were 
verified using Student’s t tests. The effects of fasting on IGF-II, IGF-I, 
IGFBP-2 and insulin levels within each group were statistically evaluated 
using the Wilcoxon matched pairs signed rank test. The Wilcoxon rank 
sum test was used to compare IGFBP levels detected in serum from 
transgenic mice and controls by ligand blot analysis. 
Results 
Construction of PEPCK-IGF-II and generation of transgenic 
mice 
As outlined in Fig. 1, a human IGF-II cDNA was placed 
under the transcriptional control of 550 bp of the PEPCK 
promoter. According to the findings of Palmiter et al. (29), 
we introduced a heterologous intron [intron A of the rat 
insulin II (ins-2) gene] up-stream of the IGF-II cDNA to 
facilitate expression in transgenic mice. 
Two transgenic founder mice (525-41 and 526-51) were 
produced by pronuclear microinjection, which transmitted 
the PEPCK-IGF-II transgenes to their offspring. Southern 
blot analyses of DNA samples from Fl offspring are shown 
in Fig. 2. The percentage of transgenic offspring indicated 
that both founder mice were mosaics. In subsequent gener- 
B 
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FIG. 2. Southern blot analysis of Fl offspring from founder animals 
525-41 (A) and 526-51 (B). Tail DNA (10 pg) was digested with PstI, 
electrophoresed, and blotted, as described in Materials and Methods. 
The blots were hybridized with a “P-labeled 782-bp IGF-II cDNA 
probe, washed, and exposed to x-ray film (36 h). Transgenic animals 
are marked by arrows; mol wt markers are shown at the right of the 
blots. 
ations, matings of hemizygous transgenic mice with controls 
produced about 50% transgenic offspring. All transgenic 
mice investigated in this study were hemizygotes, and all 
controls were their nontransgenic littermates. 
Expression of PEPCK-IGF-II gene constructs 
Steady state levels of PEPCK-IGF-II mRNA expression 
were studied by Northern blot analysis of total RNA from a 
variety of organs. RNA from liver, kidney, and intestine, 
major sites of endogenous PEPCK expression (30, 31), were 
used to compare transgenic animals from both lines with 
controls. A transgene-specific RNA of about 1 kb was de- 
tected in organ samples from line 525-41 (Fig. 3A). We, 
therefore, concentrated our further studies on this line and 
tested a wide spectrum of organs for PEPCK-IGF-II-specific 
-23 
Liver (10 pg) Intestine (2 vg) Kidney (5 pg) 
418s 
FIG. 3. Northern blot analysis of steady state levels of PEPCK-IGF- 
II-specific mRNA. A, Comparison of the two transgenic lines with 
controls. Total RNA was purified from liver, intestine, and kidney of 
g-week-old transgenic mice and a control after a 14-h fasting period, 
as described in Materials and Methods, glyoxylated, electrophoresed on 
1.1% agarose gels, transferred to Hybond N filters (Amersham), and 
hybridized with a 3*P-labeled IGF-II riboprobe. After washing under 
stringent conditions, the filter was exposed to x-ray film (8 h). The 
amount of RNA loaded per slot is indicated as well as the relative 
mobility of mol wt markers (right side). A transgene-specific transcript 
of about 1 kb was detected in line 525-41. B, Expression pattern of 
line 525-41. Total RNAs from 17 different tissues of an ad libitum-fed 
12-week-old male transgenic mouse were subjected to Northern blot 
analysis, as described above. From the organs investigated, transgene- 
specific transcripts were present in liver, duodenum, jejunum, ileum, 
colon, and kidney. The relative mobilities of 18s and 28s ribosomal 
RNAs are indicated at the right side. 
1880 IGF-II TRANSGENIC MICE Endo. 1994 
Vol. 135, No. 5 
mRNA expression. In addition to liver and kidney, we de- 
tected a transgene-specific transcript in several parts of the 
gut (duodenum, jejunum, ileum, and colon, but not caecum). 
No PEPCK-IGF-II expression was found in adipose tissue 
(Fig. 3B). 
Serum IGF-II concentrations in transgenic mice belonging 
to line 525-41 were 2- to 3-fold higher than those in controls, 
with significantly greater IGF-II levels in male than in female 
mice (Fig. 4A). Circulating IGF-II levels were not different 
between transgenic animals younger or older than 12 weeks 
(Fig. 4B). After a 14-h fasting period, circulating IGF-II levels 
increased in transgenic mice (P < 0.05), but decreased in 
controls (P < O.Ol), suggesting correct nutritional control of 
the PEPCK promoter-driven transgene (Fig. 5). 
Effects of elevated IGF-II on IGF-I, IGFBP, insulin, and 
glucose levels 
Overall, serum IGF-I concentrations were lower in IGF-II 
transgenic mice than in controls. LSMs and SES (in parenthe- 
ses) of LSMs calculated for transgenic and control mice using 
the statistical model outlined in Materials and Methods were 
A IGF-II IGF-I IGFBP-2 
hW1 WmU [wlmll 
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FIG. 4. Effects of sex (A) and age (B) on concentrations of IGF-II, 
IGF-I, and IGFBP-2 in serum samples from PEPCK-IGF-II transgenic 
mice and controls. Measurements were performed as described in 
Materials and Methods in 99 serum samples from transgenic mice (4- 
25 weeks old) and in 132 serum samples from controls (4-20 weeks 
old). Analysis of variance was used to calculate LSMs (columns) and 
SE (error bars) for male and female mice (A) or mice belonging to 
different age classes (B). Significant differences are marked by uster- 
isksz *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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FIG. 5. Effects of fasting on concentrations of IGF-II, IGF-I, IGFBP- 
2, insulin, and glucose in serum samples from PEPCK-IGF-II trans- 
genie mice and littermate controls. Serum samples were obtained from 
lo- to 20-week-old transgenic mice (n = 11) and controls (n = 12) 
before (N) and after (F) a 14-h food deprivation period. Measurements 
were carried out, and data were subjected to analysis of variance as 
described in Materials and Methods. Columns reuresent LSMs esti- 
mated for transgenic mice and controls. SEs of LSM are shown as error 
bars. Significant differences between LSMs from both groups are 
marked by asterisks: **, P < 0.01; ***, P < 0.001. 
327.9 (7.4) and 362.0 (6.5), respectively (P < 0.001). Sex- 
related differences in IGF-I levels were seen in both groups 
of mice. Transgenic males displayed significantly lower IGF- 
I levels than transgenic females, suggesting a negative rela- 
tionship between IGF-I and IGF-II levels (Fig. 4A). A negative 
correlation between IGF-II and IGF-I levels in PEPCK-IGF- 
II transgenic mice was also shown by linear regression analy- 
sis (Fig. 6A). Serum IGF-I levels in male controls were 
significantly higher than those in control females (Fig. 4A). 
An effect of age on serum IGF-I concentrations was seen in 
the control group in which animals younger than 12 weeks 
had significantly higher levels than older mice. 
Serum IGFBP-2 was significantly elevated in PEPCK-IGF- 
II transgenic mice, with a sex-related difference mirroring 
that observed with IGF-II (Fig. 4A). In controls, IGFBP-2 
levels in male and female mice were not significantly differ- 
ent. An effect of age was seen in both groups of mice 
investigated (Fig. 4B): animals younger than 12 weeks had 
significantly higher IGFBP-2 values than older animals. 
Linear regression analysis revealed a significant positive 
correlation between serum IGF-II and IGFBP-2 levels as well 
as a significant negative correlation between serum IGF-I 
and IGFBP-2 in PEPCK-IGF-II transgenic mice (Fig. 6, B and 
0 
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FIG. 7. Ligand blot analysis of IGFBPs in serum from 12-week-old 
PEPCK-IGF-II transgenic mice (T) and controls (C). A, Ligand blot 
analysis was carried out as described in Materials and Methods, using 
[1251]IGF-II as tracer. The relative moi wt of IGFBP-3 (45 kDa), 
IGFBP-2 (30 kDa), and IGFBP-4 (20 kDa) is indicated at the right 
side. B, IGFBPs were quantified as described in Materials and Methods. 
The graph shows the means and SDS. Serum IGFBP-2 in transgenic 
mice was significantly higher than that in controls (P < 0.01). Fur- 
thermore, transgenic mice tended to have elevated serum concentra- 
tions of IGFBP-3 (P = 0.0736) and IGFBP-4 (P = 0.0967). 
Ligand blot analysis of serum from 12-week-old animals 
confirmed the difference in IGFBP-2 levels between trans- 
genie mice and controls. Similarly, serum concentrations of 
IGFBP-3 and IGFBP-4 tended to be higher in transgenic mice 
than in controls (Fig. 7). 
Effects of fasting on IGF-I, IGFBP-2, insulin, and glucose 
levels 
These effects are summarized in Fig. 5. After a 14-h fasting 
period, serum IGF-I levels were reduced in both groups of 
mice (P < O.Ol), but more markedly in transgenic mice than 
in controls, reflecting again the negative relationship between 
IGF-II and IGF-I. 
IGFBP-2 was up-regulated by fasting in both groups of 
mice investigated, again more markedly in transgenic mice 
(70%; P C 0.001) than in controls (40%; P < 0.01). 
Under ad libitum feeding, serum insulin concentrations 
were slightly, but not significantly, lower in transgenic mice 
than in controls, whereas 14-h food deprivation resulted in 
significantly reduced insulin levels in transgenic mice com- 
FIG. 6. Linear regressions and correlations between IGF-II and IGF-I 
(A) as well as IGF-II and IGFBP-2 (B) and IGF-I and IGFBP-2 (C) in 
serum samples from PEPCK-IGF-II transgenic mice (T; 0) and con- 
trols (C; 0). 
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pared to controls. In contrast, fasting glucose levels were not 
significantly different between the two groups of mice. 
Effects of elevated IGF-II on body and organ growth 
Data obtained from 4- and 12-week-old PEPCK-IGF-II 
transgenic mice and controls are presented in Tables 1 and 
2. Although there were no significant differences between 
the groups, transgenic mice displayed slightly higher values 
for body weight, body dimensions, carcass weight, and ab- 
dominal fat at 4 weeks of age. In 12-week-old animals, all 
of these differences were absent (Table 1). 
Determination of organ weights (Table 2) revealed signif- 
icantly greater kidney and testis weights for 4-week-old 
transgenic mice than for age-matched controls. The mean 
kidney weight of transgenic mice was also increased when 
related to body weight (6.5 X 10e3 VS. 6.1 X 10V3; P < 0.05). 
At 12 weeks of age, there were no significant differences in 
kidney or testis weight, but transgenic mice displayed signif- 
icantly higher weights of the adrenal glands than controls (P 
< 0.05). The difference in mean relative adrenal weight (1.8 
x 10e4 VS. 1.5 X 10e4) reached the borderline of statistical 
significance (P = 0.0551). 
Discussion 
The biological activities of IGFs in viva have been subject 
to extensive research. A number of studies (3,4, 32-34) used 
the gene targeting approach to generate mice deficient for 
IGF-II, IGF-I, IGF type 1 receptor, or combinations of these. 
Analysis of phenotypes resulting from the lack of IGFs and/ 
or their receptors provided a plethora of new aspects con- 
cerning their roles in prenatal and postnatal development. 
However, the evidence given is indirect, because conclusions 
are drawn from null mutants. Therefore, many studies on 
the biological function of IGF-II involved experimental de- 
signs with artificially increased local or circulating levels of 
IGF-II. 
Exogenous application of IGFs allows only short studies 
and may cause immunological problems if heterologous pro- 
teins are used. Transplantation of IGF-II-secreting tumors 
into nude mice or rats (35,36) provides a model for prolonged 
studies. However, standardization of these experiments is 
difficult because tumor growth may be variable and can 
compromise the animals. 
To overcome these problems, we generated transgenic 
mice expressing human IGF-II under the control of the 
PEPCK promoter. The gene coding for PEPCK (GTP; EC 
4.1.1.32), a pace-setting enzyme in gluconeogenesis, is ex- 
pressed in multiple tissues and regulated in a complex tissue- 
specific manner (37, 38). In the liver, CAMP, glucocorticoids, 
thyroid hormone, PRL, and retinoic acid are inducers, and 
insulin and diacylglycerol are inhibitors of expression (38). 
A bovine GH gene controlled by 460 bp of the rat PEPCK 
promoter was shown to follow the expression of the endog- 
enous PEPCK gene with respect to both developmental 
pattern and tissue specificity. Expression started on day 19 
of fetal development and increased about 200-fold after birth 
(39). Expression was detected in liver, kidney, intestine, 
adipose tissue, and mammary gland (30, 31). Starvation 
stimulated expression of the PEPCK promoter-regulated 
TABLE 1. Serum IGF-II, body weight, external body dimensions, skin weight, carcass weight, and abdominal fat of PEPCK-IGF-2 transgenic 
mice (T) and nontransgenic littermates (C) 
Parameter 
Serum IGF-II (rig/ml) 
LSM 
135.23 
60.17 
Age 4 weeks 
SE 
5.35 
4.46 
P LSM 
0.0001 137.18 
’ 52.61 
Age 12 weeks 
SE P 
4.38 0.0001 
4.38 a 
BW (8) 16.87 0.66 0.1196 30.64 0.63 0.8772 
15.49 0.55 30.50 0.63 
Crown-rump length (cm) 
Nose-rump length (cm) 
Total body length (cm) 
Skin wt (g) 
T 6.68 
C 6.60 
T 8.24 
C 8.03 
T 15.57 
C 15.16 
T 3.15 
C 2.85 
0.09 0.5009 8.73 0.08 0.9498 
0.07 8.72 0.07 
0.10 0.1164 10.46 0.08 0.3488 
0.08 10.36 0.08 
0.32 0.3329 18.80 0.24 0.5676 
0.27 19.00 0.23 
0.17 0.1995 5.82 0.16 0.6859 
0.15 5.92 0.16 
Carcass wt (g) T 6.99 0.27 0.0782 13.77 0.32 0.8050 
C 6.34 0.23 13.88 0.32 
Abdominal fat (mg) T 78.29 4.72 0.6088 916.41 76.39 0.3597 
C 75.12 3.94 816.11 76.39 
The table shows the LSMs and SES of LSMs calculated for both groups of mice investigated. Number of animals investigated per age class: 4 
weeks, T, 4& 100; C, 13d, 69; 12 weeks: T, 118, 89, C, lld,8P. LSMs of T and C mice were compared using Student’s t tests; P values are shown 
in the fifth and eighth columns, respectively, and significant differences are indicated. 
a P < 0.001. 
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TABLE 2. Organ weights of PEPCK-IGF-II transgenic mice (T) and nontransgenic littermates (C) 
1883 
organ Group 
LSM 
Age 4 weeks 
SE P LSM 
Age 12 weeks 
SE P 
Heart (mg) 
Lung bg) 
Spleen (mg) 
Pancreas (mg) 
Kidney (mg) 
Adrenal gland (mg) 
Liver (mg) 
Gastroenteric tract (g) 
Thymus (mg) 
Salivary gland (mg) 
Brain (mg) 
Testis (mg) 
: 
T 
C 
T 
C 
: 
T 
C 
T 
C 
: 
T 
C 
T 
C 
T 
C 
T 
C 
: 
93.06 3.25 
85.36 2.71 
151.38 3.45 
148.95 2.88 
104.35 4.52 
96.61 3.77 
20.75 3.36 
26.98 2.56 
110.10 
94.59 
4.73 
3.95 
2.58 0.19 
2.37 0.16 
999.65 46.41 
912.46 38.72 
3.18 0.12 
2.91 0.10 
97.81 6.63 
89.32 5.53 
133.17 6.73 
135.83 5.62 
430.92 
423.22 
52.11 
40.37 
4.06 
3.39 
2.79 
1.55 
0.0794 
0.5926 
0.1990 
0.1520 
0.0177 
a 
0.4196 
0.1599 
0.1020 
0.3308 
0.7643 
0.1566 
0.0022 
b 
155.75 4.57 
159.46 4.57 
223.68 4.92 
218.57 4.92 
136.88 9.92 
131.46 9.92 
50.36 6.98 
55.51 6.98 
218.06 8.46 
206.97 8.29 
5.27 0.25 
4.50 0.25 
1556.61 50.05 
1649.47 50.05 
4.34 0.17 
4.23 0.17 
55.23 2.84 
52.52 2.84 
227.69 10.53 
231.83 10.53 
446.26 6.14 
446.89 6.14 
93.82 4.65 
102.64 4.65 
0.5693 
0.4678 
0.7021 
0.6054 
0.3562 
0.0341 
D 
0.1983 
0.6248 
0.5043 
0.7823 
0.9419 
0.1950 
The table shows the LSMs and SES of LSMs calculated for both groups of mice investigated. Number of animals investigated per age class: 4 
weeks: T, 4& 109, C, 13& 60, 12 weeks: T, 11&8P; C, 116, 89. LSMs for T and C mice were compared using Student’s t tests; P values are shown 
in the fifth and eighth columns, respectively, and significant differences are indicated. 
D P < 0.05. 
b P c 0.01. 
transgene, which was also seen in our study. 
As a consequence of PEPCK-IGF-II transgene expression, 
we observed a number of endocrine changes. A negative 
relationship between serum IGF-II and IGF-I levels in 
PEPCK-IGF-II transgenic mice might be due to displacement 
by IGF-II of IGF-I from IGFBPs, mainly IGFBP-3, which is 
the most abundant IGFBP in the circulation (40,41). IGFBP- 
3 was slightly, but not significantly, elevated in PEPCK-IGF- 
II transgenic mice. The IGF levels measured reflect almost 
exclusively IGF peptides bound to IGFBPs, as the half-lives 
of free IGFs in the circulation are very short (42). In contrast 
to PEPCK-IGF-II transgenic mice, circulating IGFBP-3 in- 
creased significantly in IGF-I transgenic mice in both the 
presence and absence of GH, suggesting that IGF-I, rather 
than GH, is the primary regulator of serum IGFBP-3 (43). 
Furthermore, a recent study showed elevated IGF-I and 
IGFBP-3 serum levels in transgenic mice with inducible ovine 
GH gene expression (44). However, this model is not suitable 
to separate the effects of IGF-I on circulating IGFBP-3 levels 
from those of GH. 
to stimulate increases in serum IGFBP-2 (43). IGFBP-2 is the 
second most abundant IGFBP in the circulation and may act 
primarily as an IGF-II-BP, as its affinity for IGF-II is 1 order 
of magnitude higher than that for IGF-I (45). A comparison 
of mouse, rat, and human IGFBP-2 sequences revealed a 
high degree of homology among all three species (46). Al- 
though little is known so far about the regulation of IGFBP- 
2, a working hypothesis has emerged that IGFBP-2 is mainly 
regulated by its primary ligand, IGF-II (23). PEPCK-IGF-II 
transgenic mice show significantly elevated serum IGFBP-2, 
with a sex-related difference mirroring that observed with 
IGF-II. Furthermore, linear regression analysis revealed a 
significant positive correlation between IGF-II and IGFBP-2 
levels in PEPCK-IGF-II transgenic mice, providing direct 
experimental evidence that IGF-II is a major regulator of 
IGFBP-2. The significant negative correlation between IGF-I 
and IGFBP-2 may primarily be due to the negative relation- 
ship between IGF-I and IGF-II. Although IGF-I is capable of 
increasing serum IGFBP-2 (43), up-regulation of IGFBP-2 
obviously does not depend on an increase in serum IGF-I. 
Overexpression of IGF-I in transgenic mice was also found The observation that in both groups of mice animals 
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younger than 12 weeks had significantly higher IGFBP-2 
values than older animals is consistent with findings in 
humans, in which IGFBP-2 levels are high at birth, decline 
by late puberty, and increase again with aging (23). IGFBP- 
2 was up-regulated by fasting, which was also found in 
humans (23) and rats (47). The greater increase in IGFBP-2 
levels in transgenic mice (70%) than in controls (40%) indi- 
cates a synergistic effect of elevated IGF-II and fasting on 
IGFBP-2 levels. 
Fasting insulin concentrations in serum from PEPCK-IGF- 
II transgenic mice were significantly lower than those in 
controls. A reduction of insulin levels is also found in patients 
suffering from nonislet cell tumor-induced hypoglycemia 
due to large tumors producing excessive amounts of IGF-II 
or its prohormone forms (48). In contrast to these patients, 
PEPCK-IGF-II transgenic mice are not hypoglycemic. This 
may be due to a difference in the absolute level of IGF-II 
produced or a difference in the relative amount of IGFBPs 
that could block the hypoglycemic action of excessive IGF- 
II. IGFBP-3 is low in nonislet cell tumor-induced hypogly- 
cemia, and its increase after GH therapy results in alleviation 
of hypoglycemia (49). A study of the acute action of IGF-II 
on glucose metabolism in adult rats showed that compared 
to insulin, about 50 times higher doses of IGF-II were re- 
quired to produce identical in vim responses (50). The hy- 
pothesis that the development of hypoglycemia as a conse- 
quence of elevated IGF-II may be dose dependent is sup- 
ported by a recently published study on transgenic mice 
expressing IGF-II under the transcriptional control of the 
MUP promoter (51). A line of mice with a mean circulating 
IGF-II level of 454 rig/ml showed a 20% reduction in glucose 
levels throughout life; another transgenic line with an aver- 
age serum IGF-II level of 243 rig/ml developed hypoglycemia 
with increasing age. Furthermore, a large reduction in body 
fat was observed in both of these lines, but the mechanism 
for this metabolic effect of IGF-II is still unclear. Our esti- 
mations of the body compositions of 4- and 12-week-old 
PEPCK-IGF-II transgenic mice did not suggest a significant 
reduction in body fat. 
In addition to a number of endocrine consequences, ele- 
vated IGF-II in transgenic mice had subtle effects on the 
growth of several organs, which can at least in part be 
explained by findings of other studies. The roles of different 
growth factors, including IGFs, in kidney development have 
recently been reviewed by Hammerman et al. (52). IGF-II is 
expressed in human fetal kidney, mainly in undifferentiated 
stromal and blastemal cells (53). Furthermore, IGF-I and 
IGF-II are required for the growth and development of rat 
metanephroi in vitro (54). In vim, compensatory renal growth 
after unilateral nephrectomy in immature, but not adult, rats 
was associated with increased renal IGF-I gene expression 
and enhanced specific renal binding of IGF-I and IGF-II to 
plasma membranes (55). In another study, elevated IGF-II 
levels were found in kidney tissue and serum of immature, 
but not adult, rats during compensatory kidney growth after 
uninephrectomy (56). Conversely, kidney weight was in- 
creased in nude mice transplanted with pieces of IGF-II- 
secreting Wilms’ tumors (36). As nephrogenesis of mice is 
not completed with birth (57) and PEPCK promoter-driven 
IGF-II expression in the kidney starts around birth, there is 
a common window for both phenomena that could explain 
the slightly, but significantly, increased kidney weight of 
PEPCK-IGF-II transgenic mice at the age of 4 weeks. Com- 
plex stereological investigations will be necessary to deter- 
mine the organ structures undergoing increased growth and 
to clarify why the difference in kidney weight is decreased 
at the age of 12 weeks. 
The effects of IGF-II on the adrenal gland are also well 
known. Quantitation and localization of IGF-II mRNA in the 
developing ovine adrenal gland provided evidence for an 
autocrine/paracrine role of IGF-II in vim (58). In vitro studies 
on fetal rat (59) or human adrenal cells (60) demonstrated a 
proliferative effect of IGF-II. Furthermore, IGF-II, more po- 
tently than IGF-I, stimulated bovine adrenocortical steroid- 
ogenesis through the IGF type 1 receptor (61). 
Although we observed distinct effects of IGF-II overex- 
pression on organ growth in transgenic mice, they were 
relatively small compared to those in transgenic mice express- 
ing human IGF-I (62-64) or GHs from different species (for 
review, see Ref. 65). These studies demonstrated that the 
growth-promoting actions of GH are in large part mediated 
by IGF-I, but also suggested that GH and IGF-I act inde- 
pendently in specific tissues; GH appears to stimulate liver 
growth directly, whereas IGF-I has a specific GH-independ- 
ent effect on brain growth (for review, see Ref. 66). 
The lack of major changes in body and organ growth of 
PEPCK-IGF-II transgenic mice may be due to relatively high 
levels of IGF-I persisting in these animals. The growth effects 
of IGF-II are probably mediated via the IGF type 1 receptor, 
which usually binds IGF-I with higher affinity than IGF-II 
(for review, see Ref. 67). 
A synthesis of our results and findings of studies on mice 
expressing IGF-II transgenes with different tissue specificities 
[part only available in abstract form (68-70)] will further 
specify the endocrine and auto-/paracrine effects of IGF-II. 
Specifically, it will be interesting to determine whether aging 
PEPCK-IGF-II transgenic mice develop tumors with in- 
creased frequency, as has been observed in MUP-IGF-II 
transgenic mice (51). 
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